Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12514787 | 0.82 | CYP1A2 (0.33) | NOS3NOS2CYP1A2POLBGBA1 | |
| SCHEMBL16804955 | 0.81 | DHFR (0.38) | HCRTR1HCRTR2PDE2ACYP1A2NPC1 | |
| SCHEMBL30907645 | 0.81 | HCRTR1 (0.34) | HCRTR1HCRTR2PDE2ACYP1A2NPC1 | |
| SCHEMBL7124872 | 0.79 | NOS3 (0.46) | NOS3NOS2NOS1CYP1A2POLB | |
| SCHEMBL30707617 | 0.79 | NPC1 (0.35) | HCRTR1HCRTR2PDE2ACYP1A2NPC1 | |
| SCHEMBL16783064 | 0.78 | ALDH1A1 (0.33) | HCRTR1HCRTR2PDE2ACYP1A2NPC1 | |
| SCHEMBL16367867 | 0.77 | UHRF1 (0.39) | NOS3NOS2NOS1CYP1A2MAPT | |
| SCHEMBL27862145 | 0.76 | HCRTR1 (0.34) | HCRTR1HCRTR2PDE2A | |
| SCHEMBL30907243 | 0.76 | MEN1 (0.36) | HCRTR1HCRTR2PDE2AMAPTPOLB | |
| SCHEMBL13859138 | 0.76 | HCRTR1 (0.34) | HCRTR1HCRTR2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2024-05-02 | — | — | US | disclosed |
| CN-114144230-B | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2024-04-23 | — | — | CN | disclosed |
| US-11590111-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| CN-114144230-A | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3938050-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| CN-100497333-C | Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders | HOFFMANN LA ROCHE (CH) | 2009-06-10 | — | — | CN | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| CN-1633430-A | Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders | HOFFMANN LA ROCHE (CH) | 2005-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | HCRTR1 2050/4885HCRTR2 2330/4885NOS3 4440/4885 |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | HCRTR1 1058/4885HCRTR2 1227/4885NOS3 2426/4885 |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | HCRTR1 2050/4885HCRTR2 2330/4885NOS3 4440/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | HCRTR1 2050/4885HCRTR2 2330/4885NOS3 4440/4885 |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | HCRTR1 2050/4885HCRTR2 2330/4885NOS3 4440/4885 |
| US-11590111-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | HCRTR1 2050/4885HCRTR2 2330/4885NOS3 4440/4885 |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | AADAC, NLRP3, NOD2 | HCRTR1 2633/4885HCRTR2 1875/4885NOS3 1217/4885 |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | HCRTR1 2050/4885HCRTR2 2330/4885NOS3 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.